129(top 1%)
papers
9.4K(top 1%)
citations
53(top 1%)
h-index
96(top 1%)
g-index
132
all documents
9.7K
doc citations
1.2K
citing journals

Top Articles

#TitleJournalYearCitations
1Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909Journal of Clinical Investigation2005569
2Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T LymphocytesJournal of Experimental Medicine1998475
3High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 IndividualsJournal of Experimental Medicine1999447
4Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide AnaloguesJournal of Immunology1998370
5Four Functionally Distinct Populations of Human Effector-Memory CD8+ T LymphocytesJournal of Immunology2007347
6Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analoguesJournal of Immunology1998329
7Cross-Priming of Naive Cd8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma CellsJournal of Experimental Medicine2000259
8Human natural Treg microRNA signature: Role of microRNA‐31 and microRNA‐21 in FOXP3 expressionEuropean Journal of Immunology2009252
9Cutting Edge: Cytolytic Effector Function in Human Circulating CD8+ T Cells Closely Correlates with CD56 Surface ExpressionJournal of Immunology2000232
10Cross-presenting human γδ T cells induce robust CD8 + αβ T cell responsesProceedings of the National Academy of Sciences of the United States of America2009229
11Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Cancer Immunology, Immunotherapy2008193
12In Vivo Expression of Natural Killer Cell Inhibitory Receptors by Human Melanoma–Specific Cytolytic T LymphocytesJournal of Experimental Medicine1999179
13“MIATA”—Minimal Information about T Cell AssaysImmunity2009178
14Toll‐like receptors’ two‐edged sword: when immunity meets apoptosisEuropean Journal of Immunology2007156
15Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patientsCancer Research2000140
16Cooperation of Human Tumor-Reactive CD4+ and CD8+ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCRImmunity2005136
17Ex Vivo IFN-γ Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant DiseasesJournal of Immunology2001135
18Quantitation of antigen-reactive T cells in peripheral blood by IFNγ-ELISPOT assay and chromium-release assay: a four-centre comparative trialJournal of Immunological Methods2000131
19T Cell Assays and MIATA: The Essential Minimum for Maximum ImpactImmunity2012131
20TRAF2 Deficiency Results in Hyperactivity of Certain TNFR1 Signals and Impairment of CD40-Mediated ResponsesImmunity1999128
21Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without ToleranceJournal of Experimental Medicine2002120
22Vaccination with a Melan-A Peptide Selects an Oligoclonal T Cell Population with Increased Functional Avidity and Tumor ReactivityJournal of Immunology2002113
23In vivo imaging of T cell delivery to tumors after adoptive transfer therapyProceedings of the National Academy of Sciences of the United States of America2007113
24Human Effector CD8+ T Lymphocytes Express TLR3 as a Functional CoreceptorJournal of Immunology2006112
25CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patientsEuropean Journal of Immunology1999111
26Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic MelanomaJournal of Immunology2002106
27Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activityCancer Research2001106
28Enrichment of Human CD4+ Vα24/Vβ11 Invariant NKT Cells in Intrahepatic Malignant TumorsJournal of Immunology2009103
29In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cellsEuropean Journal of Immunology200296
30Selecting highly affine and well-expressed TCRs for gene therapy of melanomaBlood200795
31Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer+ CD8+ T Cells in HumansJournal of Experimental Medicine200290
32Naturally Acquired MAGE-A10- and SSX-2-Specific CD8+ T Cell Responses in Patients with Hepatocellular CarcinomaJournal of Immunology200589
33Tetramer-Guided Analysis of TCR β-Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma PatientsJournal of Immunology200084
34The Activatory Receptor 2B4 Is Expressed In Vivo by Human CD8+ Effector αβ T CellsJournal of Immunology200182
35Discrepancy between ELISPOT IFN-  secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-lifeProceedings of the National Academy of Sciences of the United States of America200182
36Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cellsImmunology200580
37MicroRNA Profile of Circulating CD4-positive Regulatory T Cells in Human Adults and Impact of Differentially Expressed MicroRNAs on Expression of Two Genes Essential to Their FunctionJournal of Biological Chemistry201280
38Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapyTrends in Molecular Medicine199878
39A Novel Approach to Characterize Clonality and Differentiation of Human Melanoma-Specific T Cell Responses: Spontaneous Priming and Efficient Boosting by VaccinationJournal of Immunology200678
40Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide AnalogueJournal of Immunology200075
41TNF receptor 1 (TNFR1) and CD95 are not required for T cell deletion after virus infection but contribute to peptide-induced deletion under limited conditionsEuropean Journal of Immunology200072
42Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activityCancer Research200270
43Functional Avidity of Tumor Antigen-Specific CTL Recognition Directly Correlates with the Stability of MHC/Peptide Multimer Binding to TCRJournal of Immunology200267
44α3 Domain Mutants of Peptide/MHC Class I Multimers Allow the Selective Isolation of High Avidity Tumor-Reactive CD8 T CellsJournal of Immunology200365
45Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral bloodCancer Immunology, Immunotherapy200865
46Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyondCancer Immunology, Immunotherapy201165
47High Frequency of Functionally Active Melan-A–Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient MelanomaCancer Research200460
48Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine ConsortiumCancer Immunology, Immunotherapy200960
49Positional Scanning-Synthetic Peptide Library-Based Analysis of Self- and Pathogen-Derived Peptide Cross-Reactivity with Tumor-Reactive Melan-A-Specific CTLJournal of Immunology200257
50The Human T Cell Response to Melanoma AntigensAdvances in Immunology200656